Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
4.510
+0.110 (2.50%)
Jan 22, 2025, 10:42 AM EST - Market open
Adverum Biotechnologies Revenue
Adverum Biotechnologies had revenue of $1.00M in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $1.00M, down -72.22% year-over-year. In the year 2023, Adverum Biotechnologies had annual revenue of $3.60M.
Revenue (ttm)
$1.00M
Revenue Growth
-72.22%
P/S Ratio
75.18
Revenue / Employee
$8,264
Employees
121
Market Cap
93.82M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
ADVM News
- 6 weeks ago - Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients - Seeking Alpha
- 2 months ago - Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements - GlobeNewsWire
- 2 months ago - Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones - GlobeNewsWire
- 3 months ago - Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program - GlobeNewsWire
- 4 months ago - Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences - GlobeNewsWire
- 6 months ago - Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - GlobeNewsWire